{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:07:08Z","timestamp":1786122428840,"version":"build-2736575974"},"reference-count":53,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"MSD, B\u00fcrgenstrasse"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2712763","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:12:16Z","timestamp":1786097536000},"page":"2121-2134","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-6821","authenticated-orcid":false,"given":"Claudine","family":"Bommer","sequence":"first","affiliation":[{"name":"External Affairs and Market Access, MSD","place":["Lucerne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srushti","family":"Gotarkar","sequence":"additional","affiliation":[{"name":"HEDS Regional Team, Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Akyol","sequence":"additional","affiliation":[{"name":"Patient Access and Corporate Affairs, MSD","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Farajkhah","sequence":"additional","affiliation":[{"name":"HEDS Regional Team, Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-1599","authenticated-orcid":false,"given":"Dzhumber","family":"Ugrekhelidze","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Sciences, MSD","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-485X","authenticated-orcid":false,"given":"Sarah Sharon","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD","place":["Lucerne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qian","sequence":"additional","affiliation":[{"name":"HEDS Regional Team, Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11020042"},{"key":"e_1_3_5_3_1","unstructured":"Schweizerische Eidgenossenschaft\u2014Federal Statistical Office. 2026. Schweizerischer Krebsbericht 2021. https:\/\/www.bfs.admin.ch\/asset\/de\/19305696"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.04.002"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2018.14625"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602510"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5815"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-020-00052-8"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415434"},{"key":"e_1_3_5_11_1","unstructured":"Swissmedicinfo. 2026. AIPS\u2014Einzelabfrage. https:\/\/swissmedicinfo-pro.ch\/"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2095826"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S226243"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2510807"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2026.2633930"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"e_1_3_5_17_1","unstructured":"National Institute for Health and Care Excellence. 2026. Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01396-9"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.05.032"},{"key":"e_1_3_5_20_1","unstructured":"Relevancy.bger.ch. 2026. Auszug aus dem Urteil der II. sozialrechtlichen Abteilung i.S. Publisana Krankenversicherung gegen F. (Beschwerde in \u00f6ffentlich-rechtlichen Angelegenheiten). http:\/\/relevancy.bger.ch\/php\/clir\/http\/index.php?highlight_docid=atf%3A\/\/136-V-395%3Ade&lang=de&type=show_document"},{"key":"e_1_3_5_21_1","unstructured":"EMA. 2026. Keytruda EMA label. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf."},{"key":"e_1_3_5_22_1","unstructured":"Swissmedic. 2026. Swiss Summary of the Risk Management Plan (RMP) Keytruda. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/marktueberwachung\/rmp\/pembrolizumab_keytruda_rmp-summary.pdf.download.pdf\/Pembrolizumab_Keytruda-SwissRMPsummary-v1.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200717"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2023.8978"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26793"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0973"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103855"},{"key":"e_1_3_5_28_1","unstructured":"Swiss Federal Statistical Office. Swiss [Internet]; 2025. National life tables Switzerland. Available from: https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/population\/births-deaths.html"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00353-3"},{"key":"e_1_3_5_31_1","unstructured":"PS Hern\u00e1ndez Alava M Wailoo A. 2022. Estimating EQ-5D by age and sex for the UK: report by the decision support unit. https:\/\/sheffield.ac.uk\/nice-dsu\/methods-development\/estimating-eq-5d."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106047"},{"key":"e_1_3_5_34_1","unstructured":"Wolfensberger AAM Zb\u00e4ren P Althaus D et al. 2026. Empfehlungen f\u00fcr die Betreuung (Abkl\u00e4rungen Behandlung und Nachsorge) von Patienten mit Karzinomen des Kopf-Hals-Bereiches. https:\/\/www.orl-hno.ch\/fileadmin\/user_upload\/Dokumente\/Mitgliederbereich\/Arbeitsgruppen\/Hals-_und_Gesichtschirurgie\/Informationen\/Informationen\/Empfehlungen_Betreuung_Patienten_mit_Karzinomen_Kopf_Halsbereich.pdf"},{"key":"e_1_3_5_35_1","unstructured":"Federal Office of Public Health. 2026. Pr\u00e4parate Spezialit\u00e4tenliste (mit Geburtsgebrechen-Spezialit\u00e4tenliste). https:\/\/www.spezialitaetenliste.ch\/ShowPreparations.aspx"},{"key":"e_1_3_5_36_1","unstructured":"Merck & Co. Inc. Rahway NJ USA. 2023. Network meta-analysis of pembrolizumab for the first-line treatment of recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC). Technical Report."},{"key":"e_1_3_5_37_1","unstructured":"Federal Statistical Office. 2026. HVPI Schweiz (2015\u2009=\u2009100) Totalindex und 12 Hauptgruppen Ver\u00e4nderungsraten Totalindex. https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/prices\/consumer-price-index.assetdetail.21784714.html"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02625"},{"key":"e_1_3_5_39_1","unstructured":"Schweizerische Gesellschaft f\u00fcr Oto-Rhino-Laryngologie Hals- und Gesichtschirurgie. 2026. Empfehlungen f\u00fcr die Betreuung (Abkl\u00e4rungen Behandlung und Nachsorge) von Patienten mit Karzinomen des Kopf-Hals-Bereiches. https:\/\/www.orl-hno.ch\/home"},{"key":"e_1_3_5_40_1","unstructured":"Canada\u2019s Drug Agency-L\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC). 2026. Final economic guidance report: pembrolizumab (Keytruda) for melanoma adjuvant therapy. https:\/\/www.cadth.ca\/keytruda-melanoma-adjuvant-treatment-details"},{"key":"e_1_3_5_41_1","unstructured":"Canada\u2019s Drug Agency-L\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC). 2026. Final economic guidance report: pembrolizumab (Keytruda) for renal cell carcinoma. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10185PembrolizumabRCC_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf"},{"key":"e_1_3_5_42_1","unstructured":"National Institute for Health and Care Excellence. 2026. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. https:\/\/www.nice.org.uk\/guidance\/ta766"},{"key":"e_1_3_5_43_1","unstructured":"National Institute for Health and Care Excellence. 2026. Pembrolizumab for adjuvant treatment of renal cell carcinoma [TA830]. https:\/\/www.nice.org.uk\/guidance\/ta830"},{"key":"e_1_3_5_44_1","unstructured":"National Institute for Health and Care Excellence. 2026. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma [TA837]. https:\/\/www.nice.org.uk\/guidance\/ta837"},{"key":"e_1_3_5_45_1","unstructured":"National Institute for Health and Care Excellence. 2026. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [TA1017]. https:\/\/www.nice.org.uk\/guidance\/ta1017"},{"key":"e_1_3_5_46_1","unstructured":"National Institute for Health and Care Excellence. 2026. DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. http:\/\/nicedsu.org.uk\/technical-support-documents\/partitioned-survival-analysis-tsd\/"},{"key":"e_1_3_5_47_1","unstructured":"National Institute for Health and Care Excellence. 2026. DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103159"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061196"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1475502"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2417523"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.20170"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2174748"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00445-8"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2712763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2712763","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2712763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:12:21Z","timestamp":1786097541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2712763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2712763"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2712763","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}